Pharmacologic therapy for pulmonary artery hypertension

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Pulmonary arterial hypertension (PAH) is a severe condition with high mortality if untreated.
• Therapeutic options for PAH have expanded dramatically over the past 30 years.

Purpose of the Study:

• To review current pharmacotherapeutics for Pulmonary arterial hypertension (PAH).
• To discuss the evolution of PAH treatments and future directions.

Main Methods:

• Review of FDA-approved medications for PAH.
• Analysis of therapeutic strategies including monotherapy and combination therapy.
• Examination of risk assessment in guiding PAH treatment.

Main Results:

• There are currently 14 FDA-approved medications for PAH.
• Therapies target imbalances in vasoactive mediators (nitric oxide, endothelin, prostacyclin).
• Upfront combination therapy is increasingly recommended, alongside oral prostacyclin agonists.

Conclusions:

• A wide array of medications is available for PAH treatment.
• Strategic combination therapy can enhance treatment efficacy, improving morbidity and mortality.
• Ongoing research focuses on novel therapies and drug repurposing for PAH.